

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* SVLSF V, LLC (Last) (First) (Middle) ONE BOSTON PLACE 201 WASHINGTON STREET SUITE 3900 (Street) BOSTON MA 02108 (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol CATABASIS PHARMACEUTICALS INC [CATB]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) 06/30/2015	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock	06/30/2015		C		1,651,223	A	(1)	1,651,223	I	See Footnotes ⁽²⁾⁽⁴⁾
Common Stock	06/30/2015		C		34,893	A	(1)	34,893	I	See Footnotes ⁽³⁾⁽⁴⁾
Common Stock	06/30/2015		C		764,309	A	(1)	2,415,532	I	See Footnotes ⁽²⁾⁽⁴⁾
Common Stock	06/30/2015		C		16,152	A	(1)	51,045	I	See Footnotes ⁽³⁾⁽⁴⁾
Common Stock	06/30/2015		P		382,996	A	\$12	2,798,528	I	See Footnotes ⁽²⁾⁽⁴⁾
Common Stock	06/30/2015		P		8,094	A	\$12	59,139	I	See Footnotes ⁽³⁾⁽⁴⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
Series A Preferred Stock	(1)	06/30/2015		C			21,218,253	(1)	(1)	Common Stock	1,651,223	\$0	0	I	See Footnotes ⁽²⁾⁽⁴⁾
Series A Preferred Stock	(1)	06/30/2015		C			448,414	(1)	(1)	Common Stock	34,893	\$0	0	I	See Footnotes ⁽³⁾⁽⁴⁾
Series B Preferred Stock	(1)	06/30/2015		C			9,821,385	(1)	(1)	Common Stock	764,309	\$0	0	I	See Footnotes ⁽²⁾⁽⁴⁾
Series B Preferred Stock	(1)	06/30/2015		C			207,558	(1)	(1)	Common Stock	16,152	\$0	0	I	See Footnotes ⁽³⁾⁽⁴⁾

1. Name and Address of Reporting Person*

SVLSF V, LLC

(Last) (First) (Middle)

ONE BOSTON PLACE
201 WASHINGTON STREET SUITE 3900

(Street)

BOSTON MA 02108

(City) (State) (Zip)

1. Name and Address of Reporting Person*

SV Life Sciences Fund V (GP), LP

(Last) (First) (Middle)

ONE BOSTON PLACE
201 WASHINGTON STREET SUITE 3900

(Street)

BOSTON MA 02108

(City) (State) (Zip)

1. Name and Address of Reporting Person*

SV LIFE SCIENCES FUND V LP

(Last) (First) (Middle)

ONE BOSTON PLACE
201 WASHINGTON STREET SUITE 3900

(Street)

BOSTON MA 02108

(City) (State) (Zip)

1. Name and Address of Reporting Person*

SV Life Sciences Fund V Strategic Partners, L.P.

(Last) (First) (Middle)

ONE BOSTON PLACE
201 WASHINGTON STREET SUITE 3900

(Street)

BOSTON MA 02108

(City) (State) (Zip)

Explanation of Responses:

- The Series A and Series B Preferred Stock converted into Common Stock on a 1-for-12.85 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A and B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
- These shares are owned directly by SV Life Sciences Fund V, L.P. ("SVLS V LP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V LP. The general partner of SVLS V GP is SVLSF V, LLC. The members of the investment committee of SVLSF V, LLC are Kate Bingham, James Garvey, Eugene D. Hill, III, David Milne and Michael Ross. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP and SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaim beneficial ownership of the shares owned directly by SVLS V LP except to the extent of any pecuniary interest therein.
- These shares are owned directly by SV Life Sciences Fund V Strategic Partners, L.P. ("SVLS V SPP"). SV Life Sciences Fund V (GP), LP ("SVLS V GP") is the general partner of SVLS V SPP. The general partner of SVLS V GP is SVLSF V, LLC. The members of the investment committee of SVLSF V, LLC are Kate Bingham, James Garvey, Eugene D. Hill, III, David Milne and Michael Ross. SVLS V GP, SVLSF V, LLC and each of the individuals comprising the SVLSF V, LLC investment committee may be deemed to share voting, dispositive and investment power over the shares held of record by SVLS V LP and SVLS V SPP. Each of SVLS V GP, SVLSF V, LLC and the individual members of the SVLSF V, LLC investment committee disclaim beneficial ownership of the shares owned directly by SVLS V SPP except to the extent of any pecuniary interest therein.
- SVLS V LP and SVLS V SPP (each a "Fund," or collectively the "Funds") may be deemed to beneficially own the shares held by each other Fund because of certain contractual relationships among the Funds and their affiliates. The Funds disclaim beneficial ownership of shares held by any other Fund except to the extent of any pecuniary interest therein.

By: /s/ Denise Marks, Member 06/30/2015
of SVLSF V, LLC

By:/s/ Denise Marks, Member
of SVLSF V, LLC, general
partner of SV Life Sciences
Fund V (GP), L.P. 06/30/2015

By:/s/ Denise Marks, Member
of SVLSF V, LLC, general
partner of SV Life Sciences
Fund V (GP), L.P., general
partner of SV Life Sciences
Fund V, L.P. 06/30/2015

By:/s/ Denise Marks, Member
of SVLSF V, LLC, general
partner of SV Life Sciences
Fund V (GP), L.P., general
partner of SV Life Sciences
Fund V Strategic Partners, L.P. 06/30/2015

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.